| 영문 | antianginal drug | 한글 | 항협심증제 |
|---|---|---|---|
| 설명 | 협심증은 심장동맥의 혈류를 좋게하거나 심장이 혈류에 비해서 많은 일을 하는 것을 억제함으로써 치료될 수 있다. ① nitrate계통의 약물: 혈관을 이완시키는 작용을 함으로써 심장동맥의 혈류를 좋게 한다. ② 칼슘통로차단제(verapamil, nifedipine): 모든 근육의 수축에는 Ca이 관여한다. 즉 Ca이 있어야만 근육의 수축이 가능해진다. 그러므로 Ca이 세포속으로 들어가는 것을 억제하는 약제는 근육의 수축을 막는다. 이 약은 심장의 근육에 작용하여 심장 근육의 수축을 억제하며 심장이 과도하게 일하는 것을 막고, 또 심장동맥의 수축에 관여하는 근육에 작용을 하여 심장동맥을 이완시켜서 혈류를 좋게 한다. ③ 베타차단제(beta-blocker): 신체의 운동량이나 기타의 요구에 의해서 심장을 빨리 뛰게하는 신경은 바로 베타-교감신경이다. 교감신경계란 사람이 위급한 상황에서 작용하는 자율신경계이다. 즉 사람이 긴장하거나 싸울 경우에 전형적으로 교감신경계가 작용한다. 즉 심장이 뛰거나 소화가 않되거나 동공이 커지는 것 따위가 바로 교감신경계의 역할이라고 할 수 있다. 이 교감신경계에서 말초장기에 보내는 신경이 교감신경이다. 그러므로 심장에서 심장을 신체에 필요에 따라서 많은 일을 하게하는 신경을 차단할 경우에는 협심증을 치료할 수 있게 된다(심장의 산소나 기타 영양분의 수요를 줄인다). |
||
| ANDA | Abbreviated New Drug Application |
|---|---|
| NADA | New Animal Drug Application |
| ND | Doctor of Naturopathy; nasal deformity; natural death; Naval Dispensary; neonatal death; neoplastic ... |
| NDA | National Dental Association; New Drug Application; no data available; no detectable activity; no det... |
| NDS | Naval Dental School; neurologic deficit score; new drug submission; normal dog serum |
| new south wales | A state in southeastern Australia. Its capital is sydney. It was discovered by captain cook in 1770 and first settled at botany bay by marines and convicts in 1788. It was named by captain cook who thought its coastline resembled that of south wales. (12 Dec 1998) |
|---|---|
| New World leishmaniasis | A grave disease caused by Leishmania braziliensis braziliensis, endemic in southern Mexico and Central and South America, except for the equatorial region of Chile; the organism does not invade the viscera, and the disease is limited to the skin and mucous membranes, the lesions resembling the sores of cutaneous leishmaniasis caused by L. Mexicana or L. Tropica; the chancrous sores heal after a time, but some months or years later, fungating and eroding forms of ulceration may appear on the tongue and buccal or nasal mucosa; many variants of the disease exist, marked by differences in distribution, vector, epidemiology, and pathology, which suggest that it may in fact be caused by a number of closely related aetiological agents. See: espundia. Synonym: American leishmaniasis, leishmaniasis americana, nasopharyngeal leishmaniasis, New World leishmaniasis. (05 Mar 2000) |
| new yellow enzyme | The d-amino-acid oxidase found in yeast, a flavoenzyme, which contains FAD as coenzyme instead of FMN as does NADPH dehydrogenase; so-called to distinguish it from Warburg's old yellow enzyme. Compare: amino acid oxidases. (05 Mar 2000) |
| New York Heart Association classification | A functional classification to assess cardiovascular disability. Class I: patients with cardiac disease without limitation of physical activity. Ordinary activity does not cause symptoms. Class II: patients with cardiac disease with slight limitation of activity; comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or angina. Class III: patients with cardiac disease producing marked limitation of activity: comfortable at rest. Less than ordinary physical activity causes symptoms. Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present even at rest. (05 Mar 2000) |
| new zealand | A group of islands in the South Pacific Ocean. New Zealand flax. <botany> A myrtaceous shrub (Leptospermum scoparium) of new Zealand and Australia, the leaves of which are used as a substitute for tea. Source: Websters Dictionary (01 Mar 1998) |
| New Zealand mice | Inbred strains of mice, either black (NZB) or white (NZW), unique among strains used in experimental immunology because of their proclivity to spontaneous immunologic abnormalities and disorders including systemic lupus erythematosus similar to that found in humans. (05 Mar 2000) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
| rational drug design | <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it. (17 Dec 1997) |
| receptors, drug | Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. (12 Dec 1998) |
| investigational new drug |
An experimental drug tested in a clinical trial.
출처: www.mayoclinic.com/invoke.cfm
|
|---|---|
| investigational new drug |
a new therapeutic product that has been approved for clinical development. The data generated in lab and animal tests suggest its effectiveness in treating a human disease
출처: www.biotechshares.com/glossary.htm
|
| investigational new drug |
A drug that has been authorized for clinical evaluation but that is not yet approved for sale for the condition under study. An IND is granted by Health Canada.
출처: www.canadapharma.org/Patient_Pathways/Glossary_Ter...
|
| investigational new drug |
A new drug, antibiotic drug, or biological drug that is used in a clinical investigation. It also includes a biological product used in vitro for diagnostic purposes.
출처: www.acrpnet.org/resources/trial/glossary.html
|